Scarica l'app Stockscreener
793.26
1.78%
-14.39
Dopo l'orario di chiusura:
793.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Best Biotech Stocks To Add to Your WatchlistSeptember 10th - MarketBeat
Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says - marketscreener.com
REGN Maintained by HSBC -- Price Target Raised to $920 - GuruFocus
Regeneron stock gains after strong Q2 2026 earnings beat - ad-hoc-news.de
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE - globenewswire.com
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. LawsuitREGN - PR Newswire
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action - PR Newswire
REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - PR Newswire
Mathai Mammen on Betting on Big Swings to Drug the Undruggable - finance.biggo.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - globenewswire.com
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN) - Yahoo Finance
Regeneron at Wells Fargo healthcare conference: growth broadens By Investing.com - Investing.com UK
Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026REGN - Morningstar
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08 - marketscreener.com
Regeneron Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Why is Regeneron Pharmaceuticals (NASDAQ:REGN) drawing investor attention today? - Kalkine Media
Trevogrumab Clinical, Regulatory and Commercial Intelligence Report 2026: Phase II Data Show Improved Lean Mass Preservation - GlobeNewswire Inc.
(REGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
REGN 6-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock - Yahoo Finance
Did Libtayo Recall Just Shift Regeneron's (REGN) Investment Narrative? - simplywall.st
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT - GlobeNewswire
REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron stock holds firm after strong Q2 2026 results - AD HOC NEWS
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 DeadlineRGRD Law - marketscreener.com
3 Reasons to Avoid REGN and 1 Stock to Buy Instead - The Globe and Mail
1 WEEK REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - newsfilecorp.com
REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Re - natlawreview.com
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Regeneron stock holds near lofty levels as class action risk emerges - AD HOC NEWS
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile
Regeneron stock slips on a $85.2 billion market value - ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Eastern Progress
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Robbins LLP Urges REGN Investors to Contact the Firm Before - globenewswire.com
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Biotech Stocks To Watch TodaySeptember 4th - MarketBeat
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire
Regeneron stock trades lower as insider sales and lawsuit weigh on sentiment - AD HOC NEWS
Beyond the genome: Regeneron’s Abecasis on scaling drug discovery with genetic data - biocentury.com
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron stock steadies after strong Q2 figures and pipeline focus - AD HOC NEWS
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact SueWallSt - Morningstar
REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceutic - natlawreview.com
REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 - Morningstar
Regeneron Pharmaceuticals stock hits 52-week high at $847.60 By Investing.com - Investing.com Nigeria
Regeneron Pharmaceuticals stock hits 52-week high at $847.60 - Investing.com
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - globenewswire.com
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB - Yahoo Finance
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector? - Barchart.com
Why Did Regeneron Pharmaceuticals (REGN) Climb After Its Latest Update? - simplywall.st
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline - Eastern Progress
Regeneron stock gains after steady 2026 growth and legal action reminder - AD HOC NEWS
1.82%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):